摘要
目的检测羟基磷灰石纳米颗粒(HANPs)在体内的分布情况,为其体内生物安全性评价提供参考。方法在氨基化表面改性的基础上,对羟基磷灰石纳米颗粒进行125I标记,将125I标记的羟基磷灰石纳米颗粒注射到动物体内,通过放射免疫γ计数仪检测给药后30 d内体内主要组织的放射性计数,以每克组织含百分比注射剂量(%ID·g-1)评价羟基磷灰石纳米颗粒在各组织中分布情况。结果肺、肝脏和脾脏是羟基磷灰石纳米颗粒体内主要分布组织。在给药后1 d,组织蓄积量均超过5%ID·g-1;在给药后30 d内,羟基磷灰石纳米颗粒在肺组织中的蓄积量发生明显下降,而在肝脏和脾脏中则下降缓慢,蓄积量仍维持在2%ID·g-1以上。结论本实验结果表明,肺、肝脏和脾脏是羟基磷灰石纳米颗粒体内生物安全性评价应重点关注的效应组织。
OBJECTIVE To investigate the in vivo tissue distribution of hydroxyapatite nanoparticles （HANPs） and provide important information for the in vivo biosafety evaluation of HANPs. METHODS The HANPs were modified with aminopropyltriethoxysilane （APTS） to introduce amino groups on the surface. The modified HANPs were labeled with ^125I and injected into mice. A γ-counter was used to quantitatively assess the radioactivity of the tissues. The accumulation of HANPs in the tissues was expressed as the percentage injected dose per gram tissue （% ID·g^-1）. RESULTS The HANPs mainly accumulated in the lung, liver, and spleen. One day post- injection, the accumulation in these tissues was over 5% ID ·g^-1. During 30 d after the injection, the accumulation of HANPs in the lung decreased quickly, while the accumulation in the liver and spleen reduced moderately and maintained at more than 2% ID·g^-1 CONCLUSION This study indicates that lung, liver and spleen are the main tissues for the in vivo biosafety evaluation of HANPs.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2015年第8期695-699,共5页
Chinese Pharmaceutical Journal
基金
浙江省自然科学基金资助项目(Y4110665)
浙江省公益技术应用研究项目(2012C33115)
